Personalizing Antiplatelet Therapies for Acute Coronary Syndrome (ACS) in Patients Undergoing Percutaneous Coronary Intervention (PCI): Are They Cost-effective?
Cardiovasc Drugs Ther
.
2017 Feb;31(1):1-3.
doi: 10.1007/s10557-017-6720-7.
Authors
Bijan J Borah
1
,
Naveen Pereira
2
,
Michael E Farkouh
3
Affiliations
1
Economic Evaluation Service, Kern Center for the Science of Healthcare Delivery, Mayo Clinic, Rochester, MN, USA.
2
Department of Cardiovascular Diseases, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA.
3
Peter Munk Cardiac Centre & Heart and Stroke Richard Lewar Centre, University of Toronto, Toronto, Canada. michael.farkouh@uhn.ca.
PMID:
28251381
DOI:
10.1007/s10557-017-6720-7
No abstract available
Publication types
Editorial
Comment
MeSH terms
Acute Coronary Syndrome*
Cost-Benefit Analysis
Humans
Percutaneous Coronary Intervention*
Platelet Aggregation Inhibitors
Substances
Platelet Aggregation Inhibitors